title: Ultrafiltration for acute decompensated heart failure: cost, reimbursement, and financial impact.
abstract: In addition to the proposed pathophysiologic mechanisms whereby ultrafiltration (UF) can be advantageous over diuretics in the treatment of heart failure, there can also be financial and resource-utilization reasons for pursuing this extracorporeal strategy. In those cases in which the clinical outcomes would be equivalent, however, the decision whether to pursue UF will depend greatly on the anticipated hospitalization length of stay (LOS), the patient population's pay or mix, the needs and costs for high-acuity (eg, intensive care unit) care, and widely varying expenses for the equipment and disposable supplies. From a fiscal perspective, the financial viability of UF programs revolves around how improvements in LOS, resource utilization, and readmissions relate to the typical diagnosis-driven (eg, diagnosis-related group) reimbursement. We analyzed the impact of these various factors so as to better understand how the intensity (and expense) of pharmaceutical and extracorporeal therapies impacts a single admission, as well as to serve as the basis for developing strategies for optimizing long-term care.
authors.affiliation: Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, FL 32610, USA. rossea@medicine.ufl.edu
authors.forename: Edward A
authors.initials: EA
authors.lastname: Ross
authors.forename: Frank B
authors.initials: FB
authors.lastname: Bellamy
authors.forename: Scott
authors.initials: S
authors.lastname: Hawig
authors.forename: Amir
authors.initials: A
authors.lastname: Kazory
mesh_terms: D003953:Diagnosis-Related Groups / Q000191:economics / Q000706:statistics & numerical data; D004232:Diuretics / Q000191:economics / Q000627:therapeutic use; D017048:Health Care Costs; D006295:Health Resources / Q000706:statistics & numerical data; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000706:statistics & numerical data*; D007902:Length of Stay / Q000706:statistics & numerical data; D006278:Medicare / Q000191:economics / Q000706:statistics & numerical data; D014462:Ultrafiltration / Q000191:economics / Q000379:methods*; D014481:United States
chemical_list: D004232:Diuretics